In both HSALR and TfR1hu/mu, DMSXLTg mouse models and non-human primates, this approach shows robust DMPK knockout, splice correction, and phenotypic improvement with low, infrequent dosing, indicating promise as a systemic DM1 therapy [138]. This evidence concerns the gene DMPK and myotonic dystrophy type 1.